Francesco Maria Lavino
Chief Executive Officer at F2G Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrick Volkert Vink | M | 60 |
F2g Inc.
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 9 years |
| Pamela Craig | F | 67 | 9 years | |
| Paul Rothman | M | 65 | 9 years | |
| Chirfi Guindo | M | 58 | 13 years | |
| John H. Rex | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Saiyed Mahmood | M | 48 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Allan Gabor | M | - | 11 years | |
| Camilla Soenderby | F | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 3 years |
| Peter Dannenbaum | M | - | 7 years | |
| Anderson Timothy | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Richard DeLuca | M | 61 | 13 years | |
| Sylvie Grégoire | M | 62 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Ralf Schmid | M | 57 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 8 years |
| Simona Heidempergher | F | 56 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Mike Birch | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Dean Li | M | 62 | 7 years | |
| Tony Kennedy | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Naveed Iqbal Siddiqi | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
| Will West | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Perez | M | 59 | 12 years | |
| Michael Bonney | M | 65 | 20 years | |
| Michael Tomsicek | M | 58 | 5 years | |
| Thomas DesRosier | M | 69 | 2 years | |
| Richard Clark | M | 77 | 6 years | |
| David McGirr | M | 69 | 12 years | |
| Lonnie Moulder | M | 66 | 5 years | |
| Taylor Sandison | M | 52 | 1 years | |
| John Noseworthy | M | 71 | - | |
| Michael Nally | M | 48 | 10 years | |
| Alison Lawton | F | 62 | 2 years | |
| Nancy Hutson | M | 74 | 7 years | |
| Mark Corrigan | M | 66 | 7 years | |
| Jane Ellen Henney | M | 76 | 2 years | |
| Martin Rosenberg | M | 78 | 9 years | |
| Ian James Nicholson | M | 64 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 8 years |
| Thomas Shenk | M | 77 | 11 years | |
| Natarajan Sethuraman | M | 62 | 10 years | |
| J. Singleton | M | 71 | 11 years | |
| Michael B. Wood | M | 78 | 9 years | |
| Sheila Ranganath | F | - | 5 years | |
| Harry R. Jacobson | M | 76 | 3 years | |
| Brian Piekos | M | 49 | 5 years | |
| Steven Goldstone | M | 78 | 6 years | |
| Charles Kidder | M | 79 | 12 years | |
| Arthur Santora | M | 73 | 28 years | |
| René Russo | M | 49 | 12 years | |
| Guy Patrick M. Eiferman | M | - | 4 years | |
| Timothy Murphy | M | 56 | 4 years | |
| Sachin Jain | M | 43 | 2 years | |
| Milenko Cicmil | M | - | - | |
| Larry G. Edwards | M | 52 | 1 years | |
| Hugo Wahnish | M | - | 18 years | |
| Yao Lee | M | 54 | 3 years | |
| James Swanson | M | 58 | 8 years | |
| Carlos Lugo | M | - | 2 years | |
| Thomas Cannell | M | 62 | 1 years | |
| John Renger | M | 55 | 15 years | |
| William Steinkrauss | M | 39 | 3 years | |
| Arnaub Chatterjee | M | - | 5 years | |
| Marvin Johnson | M | 61 | 2 years | |
| Joseph Eid | M | 56 | - | |
| David Parry | M | - | 2 years | |
| Jerald Korn | M | 45 | 2 years | |
| Yanni Souroutzidis | M | - | 2 years | |
| Lucinda Quan | F | 51 | 2 years | |
| Bumpus Durso | F | 54 | 6 years | |
| Quentin Roach | M | 57 | 4 years | |
| Daniel Pascheles | M | - | 11 years | |
| Steven Hubrig Koehler | M | 73 | 2 years | |
| Renu Vaish | F | - | 1 years | |
| Richard Kender | M | 68 | 35 years | |
| Peter Kim | M | 65 | 5 years | |
| Martin Duvall | M | 62 | 1 years | |
| Mary Thistle | F | 64 | 6 years | |
| Joseph Farmer | M | 52 | 3 years | |
| Willie Deese | M | 68 | 12 years | |
| James Christopher Scalet | M | 65 | 9 years | |
| Angelique M. Carbo | F | 59 | 2 years | |
| Christina Morrison | F | 57 | 4 years | |
| Pam Cheng | F | 53 | 5 years | |
| Michael Rosenblatt | M | 76 | 32 years | |
| Roy Baynes | M | 69 | - | |
| C. Nicholson | M | 69 | 2 years | |
| Mervyn Turner | M | 77 | 2 years | |
| Michael Holston | M | 61 | 6 years | |
| Andrew Davis | M | 38 | 1 years | |
| Cuong Viet Do | M | 58 | 3 years | |
| Simon D. Kelner | M | 51 | 13 years | |
| Charles Laranjeira | M | 58 | 4 years | |
| Kathleen Metters | M | 66 | 13 years | |
| Roger Pomerantz | M | 67 | 3 years | |
| Pernilla Sandwall | F | 61 | 8 years | |
| Geralyn S. Ritter | F | - | 8 years | |
| Jason Pesile | M | 50 | 2 years | |
| Terrie Curran | F | 55 | 4 years | |
| Graham Lumsden | M | 64 | 26 years | |
| D. Gilliland | M | 69 | 4 years | |
| Nancy Thornberry | F | 67 | 9 years | |
| Barry Goldstein | M | - | 5 years | |
| Jonathan Robbins | M | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 88 | 88.00% |
| United Kingdom | 13 | 13.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Francesco Maria Lavino
- Personal Network
